Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (“ITP”). Positive results from ESLIM-01 ...

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHME ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Chinese biopharma Hutchmed today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib ...

Not all human foods are good for dogs; some of them can shut down a dog’s kidneys fast or set off a chain reaction that ends ...

Investing.com -- HUTCHMED (NASDAQ:HCM) stock gained 1.9% in premarket trading Wednesday after the company announced that its Phase III trial of sovleplenib in patients with warm antibody autoimmune ...

The FDA approved mitapivat (Aqvesme) as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, a rare inherited blood disease that affects hemoglobin production. An oral ...

Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Everyday physical complaints like cracked lips, dandruff, dry skin, restless legs, and mouth ulcers can signal underlying ...